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HYPERKALEMIA: A POTENTIALLY LETHAL
CLINICAL CONDITION
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SUMMARY • Hyperkalemia develops when the regulation between potassium intake and potas-
sium excretion, or the distribution between intra- and extracellular potassium is disturbed. It is a
common, silent, and potentially lethal clinical condition, which seldom occurs in patients with nor-
mal renal function. Clinically, the most important effect of hyperkalemia is that which the condition
has on the myocardium, but it also affects neuromuscular, gastrointestinal, and hormonal function-
ing. The management of hyperkalemia requires exclusion of pseudohyperkalemia, assessment of the
urgency for treatment, and institution of appropriate therapy. The initial treatment for life-threaten-
ing hyperkalemia should always include insulin plus glucose, as the hypokalemic response to insulin
is both prompt and predictable. Combined treatment with β2-agonists and insulin is also effective,
but the most rapid method of potassium removal is hemodialysis.
Key words: Hyperkalemia, physiopathology; Hyperkalemia, therapy; Kidney, physiopathology
Correspondence to: Professor Petar Kes, M.D., Ph.D., Department of
Nephrology and Dialysis, Sestre milosrdnice University Hospital,
Vinogradska c. 29, HR-10000 Zagreb, Croatia
Received January 3, 2001, accepted June 18, 2001
Introduction
Hyperkalemia is rarely encountered in healthy subjects
because of the effective cellular buffering of acute potas-
sium loads and renal excretion of excess potassium that
occurs within 6 hours. Thus, an average daily potassium
load (100 mmol/day) if given acutely, would result in frank
hyperkalemia were it not for extrarenal potassium homeo-
static mechanisms that rapidly translocate the adminis-
tered potassium into the intracellular compartment. The
extrarenal mechanisms that govern internal potassium
distribution include hormones such as insulin, epineph-
rine, and aldosterone. In addition, acid-base status and
plasma osmolality influence internal potassium balance1.
The gastrointestinal tract, which normally contributes
little to potassium excretion, assumes a greater role in the
maintenance of potassium homeostasis in patients with
chronic renal failure (CRF).
Potassium Adaptation
The mechanism of potassium adaptation in renal fai-
lure appears to be similar to the process which occurs in
subjects with intact renal function given a high potassium
diet. Renal adaptation was demonstrated as early as 24
hours following partial renal ablation in experimental
animals, and micropuncture studies suggest that net po-
tassium excretion occurs between the end of distal tubule
and the end of collecting tubule. There is an increase in
both the number and activity of the sodium • potassium
pump in the collecting tubule cells. The increased activ-
ity is not a nonspecific event secondary to the hypertro-
phic changes taking place, since the sodium • potassium
• ATPase site density is increased out of the proportion
to the increase in basolateral membrane surface area. The
renal medullary structures may also contribute to renal
potassium adaptation. The intrinsic capacity for potassium
secretion is increased in deeper nephrons. Increased de-
livery of potassium to the juxtamedullary nephrons may
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also contribute to the increased excretion of potassium by
these nephrons. Additionally, potassium recycling allows
for the secretion of any potassium that might have diffused
back from the cortical collecting duct into the interstitial
medulla, thus increasing the efficiency of the kidney to
excrete potassium2. The renal adaptive changes in potas-
sium excretion in response to a reduction in nephron mass
are largely dependent on intact aldosterone secretion and
adequate sodium delivery. Aldosterone concentrations are
often elevated in patients with renal failure, probably as
an adaptive response to reduced renal mass, which helps
prevent hyperkalemia. With a normal potassium intake,
potassium retention does no occur until a glomerular fil-
tration rate (GFR) of 5 to 10 ml/min is reached. How-
ever, if potassium intake is acutely increased, hyperkale-
mia may ensue despite a relatively preserved glomerular
filtration (e.g., 10 to 40 ml/min)2,3.
In the presence of renal failure, adaptive changes in the
colonic mucosa permit an increase in the amount of po-
tassium excreted by the colon. Rectal excretion of potas-
sium in end-stage renal disease (ESRD) patients may be
by up to 200% greater than in the normal subjects4, and
increased activity of sodium • potassium • ATPase in the
colonic mucosa of such patients has been reported5. Al-
dosterone receptors are present in colonic mucosa, and a
role for mineralocorticoids in this adaptive response has
also been suggested.
Definition
Hyperkalemia is defined as a serum potassium concen-
tration greater than 5.5 mmol/l. It seldom occurs in pa-
tients with normal renal function. Like hypokalemia, it is
often due to iatrogenic (treatment-induced) causes. While
less common than hypokalemia, it is often more danger-
ous since cardiac arrest is more often associated with high
serum potassium levels (>7.0 mmol/l)6.
Etiology
Hyperkalemia develops when the regulation between
potassium intake and excretion, or the distribution be-
tween intra- and extracellular potassium is disturbed. The
etiology of hyperkalemia is summarized in Table 1.
Pseudohyperkalemia
Spurious hyperkalemia is an artifically elevated potas-
sium concentration resulting from potassium leakage from
the cells during blood drawing or after blood collection.
Hemolysis that occurs during a traumatic blood draw is the
most common cause of pseudohyperkalemia. A prolonged,
tight tourniquet and repeated fist clenching may also re-
sult in artificially elevated potassium concentration. If the
leukocyte count is greater than 2x105/mm3, or the platelet
count is greater than 1x106/mm3, an abnormally high
amount of potassium will leak out of these cells during
coagulation, thus artificially raising the serum potassium.
Table 1. Etiology of hyperkalemia
Spurious Redistribution Renal
Ischemic blood drawing Acidosis Renal failure (severe)
Hemolysis Insulin deficiency Aldosterone deficiency
Abnormal erythrocytes Hyperosmolality AddisonÕs disease
Thrombocytosis β-Adrenergic blockade Enzymatic defects
Leukocytosis Drugs Adrenogenital syndrome
Arginine HCl Corticosterone methyloxidase
Succinylcholine Isolated aldosterone deficiency
Digitalis Hyporeninemic hypoaldosteronism
Fluoride Drugs
Hyperkalemic periodic paralysis Prostaglandin synthetase inhibitors







P. Kes Hyperkalemia: A potentially lethal clinical condition
Acta clin Croat, Vol. 40, No. 3, 2001 217
With a good blood drawing technique and analysis of
blood before clotting, a true measure of extracellular po-
tassium can be obtained. A normal serum plasma level and
an elevated serum potassium level along with the absence
of electrocardiogram (ECG) changes confirm the diag-
nosis of pseudohyperkalemia.
Transcellular shifts
A potassium shift out of cells commonly contributes
to hyperkalemia, but it alone will not result in persistent
hyperkalemia.
In the presence of acidosis, especially metabolic, po-
tassium leaks out of cells into the extracellular fluid. This
occurs as hydrogen ions enter the cells, a process which
buffers the extracellular fluid pH. Organic acids such as
that seen in lactic acidosis or diabetic ketoacidosis are less
likely to cause shifts of potassium on the basis of acidosis
alone. The lack of insulin in diabetic ketoacidosis and the
release of potassium from ischemic cells in lactic acidosis
contribute to hyperkalemia more than the acidosis per se.
Hyperglycemia produces hyperkalemia in diabetic pa-
tients by the combined effects of insulin deficiency and
hyperosmolarity on transcellular potassium distribution. An
absolute decrease in insulin as the one that occurs in type I
diabetics or in a fasting patient with ESRD may provoke
hyperkalemia7, involving not only a fasting-induced de-
crease in baseline insulin levels but also an insensitivity to
catecholamine-driven potassium uptake by cells.
Tissue ischemia which results in cell death will release
intracellular potassium (140 mmol/l) and, combined with
renal underexcretion, can result in marked hyperkalemia.
The more common clinical conditions include crushing
injuries, severe infections, and lysis of malignant cells af-
ter administration of chemotherapy, particularly in lym-
phoma, plasmacytoma, and leukemia.
Several drugs can produce hyperkalemia by altering
the transcellular distribution of potassium. Depolarizing
muscle relaxants such as succinylcholine can result in hy-
perkalemia by promoting the shift of potassium out of
cells. Patients with neuromuscular disease are especially
sensitive to the hyperkalemic effects of succinylcholine.
Infusion of 30 g of the cationic amino acid, arginine HCl,
increases plasma potassium by 0.5 to 1.0 mmol/l and can
produce life-threatening hyperkalemia in individuals with
deranged potassium metabolism. Digitalis preparations
diminish cellular potassium uptake by inhibiting the so-
dium • potassium pump. Substantial hyperkalemia can
accompany digitalis intoxication8. Fluoride intoxication
appears to increase the plasma potassium concentration
by provoking leakage from the intracellular compartment.
The associated hypocalcemia enhances the cardiac risks
of fluoride-induced hyperkalemia. ACE-inhibitors can
also result in hyperkalemia in patients with renal failure,
and the mechanism involves a decrease in aldosterone
production as the result of decreased angiotensin II lev-
els. Prolonged heparin therapy has been reported to in-
terfere with aldosterone release, resulting in hyperkalemia.
Hereditary hyperkalemic periodic paralysis is a rare
cause of hyperkalemia as the result of potassium shift out
of cells. It is inherited in an autosomal-dominant pattern.
Excessive potassium retention
In most circumstances, potassium retention occurs
because of a deficit in renal elimination. Defective urinary
excretion of potassium has three major causes: 1) renal
failure; 2) a defective mechanism of tubular potassium
excretion; and 3) hypoaldosteronism.
A normal kidney has the capacity to excrete in excess
of 400 mmol of potassium per day, and it is unlikely that
an individual will become chronically hyperkalemic with-
out some degree of chronic renal impairment. The
kidneyÕs ability to maintain homeostasis on a normal po-
tassium diet is preserved until GFR is markedly dimin-
ished (GFR <10 ml/min), but once a critical number of
nephrons have been lost, the remaining nephrons cannot
excrete a normal potassium load. To prevent hyperkale-
mia at this point, dietary potassium must be restricted (<60
mmol/day). The risk of hyperkalemia is magnified in cata-
bolic patients with acute renal failure (ARF), in whom the
daily increment in plasma potassium averages 0.7 mmol/
l or more, in contrast to the increment of 0.3 to 0.5 mmol/
l in noncatabolic patients with oliguric ARF.
Hypoaldosteronism, especially when combined with
a decrease in renal function, can substantially impair uri-
nary potassium excretion. Diminished levels of aldoster-
one result from either a primary defect in the adrenal gland
or from an abnormality in the renin • angiotensin II me-
chanism for stimulating aldosterone secretion. Hyperkale-
mia is detected in approximately half of the patients with
acquired primary adrenal insufficiency as well as in those
with two forms of adrenogenital syndrome resulting in
mineralocorticoid deficiency (C-21 hyroxylase deficiency
and deficiency in corticosterone methyloxidase I or II)9.
Decreased renin secretion may result from pathologic in-
volvement of the juxtaglomerular apparatus, defective
prostacyclin production, disordered conversion of inactive
(prorenin) to active renin (e.g., a complication of diabe-
tes mellitus), chronic expansion of extracellular fluid vol-
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ume, and acute salt restriction. Drug-induced hypoaldo-
steronism results from interference with the renin • an-
giotensin • aldosterone axis (ACE-inhibitors, prostaglan-
din synthetase inhibitors, cyclosporin), or from direct ef-
fects on the adrenal gland (heparin).
A minority of hyperkalemic patients with CRF and an
adequate GFR have normal values of aldosterone and
plasma renin activity, and apparently a primary defect in
the potassium secretory function of the distal nephron.
This abnormality has been well documented in patients
with tubulointerstitial renal diseases (e.g., medullary spon-
ge kidney, amyloidosis, sickle-cell disease, lupus erythe-
matosus, obstructive uropathy, and renal transplants), all
of which can also produce hyporeninemic hypoaldoste-
ronism.
Increased potassium intake
Hyperkalemia tends to develop in response to an in-
crease in potassium intake only when renal potassium
handling is compromised. This may occur in patients
with impaired renal function who are given large amo-
unts of potassium-rich fruits and vegetables, hyperali-
mentation fluids, multiple transfusions of blood aged in
storage, large doses of penicillin G (1.7 mmol potassium
per million units), or potassium salts (up to 13 mmol
potassium per gram)10,11. Geophagia of red clay with a
high potassium content may result in hyperkalemia in
patients with impaired renal function.
Signs and Symptoms
Hyperkalemia can cause adverse effects that range
from subtle and difficult to recognize to those that are life-
threatening. A majority of these effects are related to the
effects of potassium on cellular membrane potential or
voltage. The primary determinant of cell membrane po-
tential in most cells is the ratio of intracellular to extra-
cellular potassium concentration. Small changes in extra-
cellular potassium can result in great changes in the in-
tracellular to extracellular potassium ratio, and hence great
changes in resting membrane potential. Resting mem-
brane potential is important in all electrically active cells,
including voluntary and involuntary muscles, and neurons.
Cardiac
The most prominent effect of hyperkalemia is that on
the myocardium. Decreases in resting membrane poten-
tial decrease myocardial cell conduction velocity and in-
crease the rate of epithelization. Changes in cardiac con-
duction induced by high potassium are reflected by ECG
and generally parallel the degree of hyperkalemia (Fig. 1).
The earliest changes are tenting of T wave, which can
progress to P wave fluttering, prolongation of PR inter-
val and widening of QRS complex, with development of
a deep S-wave. A slowed conduction velocity, especially







P. Kes Hyperkalemia: A potentially lethal clinical condition
Acta clin Croat, Vol. 40, No. 3, 2001 219
in the presence of peaked T waves, increases the chance
that ventricular fibrillation may develop, leading to sud-
den death12. The progression from benign to lethal arrhy-
thmias in hyperkalemia is unpredictable, and the presence
of any ECG findings of hyperkalemia should be consid-
ered a medical emergency.
Factors exaggerating ECG changes of hyperkalemia
are low serum sodium and calcium levels as well as aci-
dosis and a high serum magnesium concentration. These
changes are counteracted by an increased calcium level,
explaining why calcium infusion is an emergency treat-
ment for serious hyperkalemia. Medications that may
aggravate hyperkalemia include heparin, procainamide,
and propranolol.
Hyperkalemia also produces conduction abnormalities
of implanted pacemakers13. In profound hyperkalemia,
the heart becomes dilated and flaccid due to decreased
strength of contraction (related to decreased number of
active muscle units).
Hemodynamic
A high potassium diet decreases blood pressure in
hypertensive humans14. The mechanism is not clear but
it could be related to its natriuretic properties, vasodilata-
tory effect, renin suppression, baroreceptor or central
neurogenic mechanisms, and in part to stimulation of the
release of endothelial cell-derived relaxing factor15.
There also are some studies suggesting that a high po-
tassium diet may protect against the development of
stroke by a mechanism distinct from its antihypertensive
properties15.
Neurologic
Skeletal muscles are particularly sensitive to hyperkale-
mia, resulting in increased weakness, fatigue, and even
paralysis related to depolarization block in the muscle.
While hyperkalemia has marked effects on the peripheral
neuromuscular system, it has little effect on the central
nervous system. Paralysis of respiratory muscles and those
required for phonation may also occur (Table 2).
Gastrointestinal
Gastrointestinal symptoms such as nausea, intermit-
tent intestinal colic, diarrhea, or even enteritis may occur
in hyperkalemic patients. These changes have been attrib-
uted to smooth muscle hyperreactivity.
Table 2. Defining characteristics of hyperkalemia
Cardiac effects:
¥ tall, peaked T wave in precordial leads
¥ widened QRS complex
¥ prolonged P-R interval
¥ decreased amplitude and disappearance of P wave




¥ vague muscular weakness (usually first sign)
¥ flaccid muscle paralysis (first noticed in the legs, later
in the trunk and arms, facial and respiration muscles af-
fected last; muscles supplied by cranial nerves are usu-
ally spared)
¥ paresthesias of the face, tongue, feet and hands are com-
mon and are the result of stimulation of pain receptors
¥ central nervous system is not affected, patient often re-
mains alert and apprehensive in spite of other changes
until cardiac arrest occurs
Gastrointestinal effects:
¥ nausea
¥ intermittent intestinal colic or diarrhea
Laboratory data:
¥ serum potassium >5.5 mmol/L
¥ often associated with acidosis
Endocrine
Hyperkalemia directly stimulates adrenal aldosterone
secretion as well as insulin and glucagon secretion, and
decreases renin secretion by an effect on the macula densa.
Sometimes, the natriuretic effects of a high potassium
level override the direct, potassium-mediated effects on
renin, so that the levels of plasma renin activity are el-
evated rather than depressed16.
Fluid and electrolytes
Hyperkalemia has a natriuretic effect. A high potas-
sium level also decreases the renal production of ammo-
nia and may directly impede ammonia secretion, leading
to the development of metabolic acidosis.
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Diagnosis
On assessing true hyperkalemia, it is useful to deter-
mine whether the potassium level is elevated as the result
of a potassium shift or due to renal underexcretion. This
determination can often be made by completing history
and routine laboratory data (Fig. 2). A 24-hour urine
potassium may be helpful if some question remains un-
solved.
can be administered as either calcium gluconate or calcium
chloride. Calcium gluconate is preferred if a peripheral
vein is used for administration, because extravasation of
calcium chloride is toxic to dermal tissue. For a patient in
cardiac arrest, treatment with calcium chloride is preferred
because of a slight delay in the action of calcium glucon-
ate. These effects can be documented on ECG within 1
to 3 min, and last for 30 to 60 min. A second dose may
be given if no effect is seen within 5 to 10 min. Because
of the rapid onset of its effect, intravenous calcium admi-
nistration should be the initial treatment for patients with
ECG abnormalities related to hyperkalemia.
Several precautions should be observed with intrave-
nous calcium: 1) it should not be administered in solutions
containing bicarbonate because CaCO3 precipitation may
occur; and 2) hypercalcemia that occurs during rapid cal-
cium infusion may potentiate the myocardial toxicity of
digitalis. Hyperkalemic patients taking digoxin should be
given calcium as a slow infusion over 20 to 30 min to avoid
hypercalcemia17.
Cellular potassium uptake
Plasma potassium level is not lowered by calcium ad-
ministration, and it must be achieved by other measures.
The second fastest way to treat hyperkalemia is to alter
potassium distribution by increasing cellular uptake with
either insulin or β2-adrenergic agonist administration.
Insulin rapidly stimulates cellular potassium uptake
by extrarenal cells, primarily hepatocytes and myocytes.
Ten units of insulin should be administered intraveno-
usly to ensure rapid and consistent bioavailability, and
will begin to affect serum potassium levels within 10 to
20 min, with the effect lasting for 4 to 6 hours17. The
higher the initial potassium, the greater was the decline
after insulin administration. Also, the higher the insu-
lin dose, the more remarkable was the effect and the
decrement of plasma potassium was often accompanied
by reversal of the ECG changes of hyperkalemia18.
When insulin was compared with other treatments for
hyperkalemia, Blumberg et al.19 found that insulin was
the most rapidly acting agent short of hemodialysis (Fig.
3). These observations further support the use of insu-
lin, together with glucose to prevent hypoglycemia, as
the most efficacious way of treating hyperkalemia in
CRF patients until dialysis is available. Glucose should
not be given to hyperglycemic patients because glucose-
induced hyperglycemia can lead to further increases in
the potassium concentration due to hypertonicity-in-
duced potassium redistribution17. Table 3 lists the studies
Fig. 2. General scheme for approaching a patient with hyperkale-
mia
Treatment
There are two aims of therapy for hyperkalemia: 1) to
reverse acute effects of hyperkalemia by increasing the
transport of potassium from extracellular fluid into cells;
and 2) to correct the underlying cause of hyperkalemia.
Since severe hyperkalemia most often occurs in a setting
of CRF, it is important to know whether or not the
mechanisms of internal potassium disposal are intact in
this setting.
Blocking cardiac effects
In the presence of ECG changes, the intravenous ad-
ministration of calcium can be life-saving, as it rapidly
counteracts the toxic effect of hyperkalemia on the myo-
cardium. This approach is universally accepted. Calcium
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that evaluated the efficacy of insulin in the treatment of
hyperkalemia.
A second effective treatment for hyperkalemia is
β2-agonist administration. Intravenous albuterol, 0.5 mg,
rapidly stimulates potassium uptake and can decrease
potassium by approximately 1 mmol/l22. Albuterol, when
administered by a nebulizer at a dose of 10 or 20 mg, de-
creases serum potassium by 0.62 or 0.98 mmol/l, respec-
tively, with an immediate onset of action and maximal
effect at 90 to 120 min23. It should be noted that the dose
used for nebulization is roughly 10 times higher than that
used for the treatment of asthma (20 mg vs 2.5 mg).
When smaller doses similar to those given to patients with
acute asthma were used (180 µg twice by inhalation), only
a minimal response was noted. Although no serious side
effects have been reported with this relatively large dose,
two potential problems may be associated with the use of
β2-agonists. One is the risk of tachyarrhythmias, and the
other is the risk of precipitation of angina pectoris in pa-
tients with coronary artery disease. Another disadvantage
of the use of these agents is that some patients with CRF
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Fig. 3. Changes in plasma potassium during intravenous infusion
of 8.5% bicarbonate solution ( n ), epinephrine ( m ), or insulin ( l ),
and during hemodialysis ( s )
Table 3. Studies examining the effect of glucose and insulin on plasma potassium
Study No. of Dose Ki Kfin ∆K Time Comments
patients (mmol/l) (mmol/l) (mmol/l)
Blumberg19 10 100 U of insulin 5.62–0.33 4.7–0.33 -0.92 60 min The greater
(ESRD) in 500 ml of the initial Ki,
20% glucose at the greater
a dose of 5 the decline
mU/kg/min
Allon20 12
(ESRD) 10 U insulin as 5.48–0.21 -0.65–0.09 Significant
i.v. bolus + 50 ml decrease
of D50 over noted at
5 min 15 min
Lens21 10
(CRF) Insulin (10 U) 6.7–0.2 5.7–0.2 -1–0.1 60 min Reversal of
i.v. bolus + 40 g ECG changes
glucose over
15 min
Ki= initial potassium; Kfin= final potassium; ∆K= potassium decrement
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Table 4. Studies examining the effect of catecholamines on plasma potassium
Study No. of Preparation Dose Ki Kfin ∆K Time Comments
patients (mmol/l) (mmol/l) (mmol/l)
Blumberg19 10 Epinephrine 0.05 5.57–0.31 5.25–0.29 NS 60 min
µg/kg/min
Allon20 12 Albuterol 20 mg in 5.56–0.22 -0.66–0.12 60 min No significant
(nebulizer) 4 ml of NS overall potassium
over 10 min -0.89–0.12 change in 4 of
in responders 10 patients




10 to 15 min
Allon24 10 Nebulized 10 mg 5.93–0.27 -0.62–0.09 90 min Two patients
albuterol resistant
10 Same 20 mg 5.81–0.41 -0.98–0.14 120 min
Ki= initial potassium; Kfin= final potassium; ∆K= potassium decrement
Table 5. Potassium removal options
Mechanism Therapy Dose Onset Duration
Antagonizes Calcium gluconate, 10% solution, 1 to 3 min 30 to 60 min
membrane effects Calcium 10 ml i.v. over 10 min
Cellular potassium Insulin Regular insulin, 10 U i.v., with dextrose, 30 min 4 to 6 h
uptake 50%, 50 ml if plasma glucose is
<13.8 mmol/l
β2-Adrenergic Nebulized albuterol, 10 mg 30 min 2 to 4 h
agonist
Potassium removal Sodium Kayexalate, 60 g p.o. in 20% sorbitol,
polystyrene or Kayexalate, 60 g per retention enema,
sulfonate without sorbitol
Hemodialysis Immediate Until dialysis is
completed
i.v.= intravenously; p.o.= perorally
Table 4 summarizes the studies that examined β-adren-
ergic-mediated extrarenal potassium disposal. In severe
hyperkalemia, combined therapy with albuterol and insu-
lin plus glucose has been shown to produce a substantially
greater decrease in potassium than that following each
drug administered separately20.
Recent studies show that the changes in serum potas-
sium with intravenous bicarbonate are small and incon-
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Fig. 4. ECG changes in a patient with extreme hyperkalemia
A patient with extreme hyperkalemia was treated with i.v. bolus of 10% calcium gluconate, 10% sodium chloride, 50% dextrose, and regu-
lar insulin followed by rapid infusion of 10% dextrose, and 8.4% sodium bicarbonate. Finally, the patient underwent hemodialysis.
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sistent (Fig. 3)19. Moreover, the associated sodium load
may worsen hypertension and contribute to the develop-
ment of acute heart failure and pulmonary edema. At pre-
sent, only in patients with hyperkalemia, metabolic aci-
dosis, and volume depletion, rehydration with 5% dextrose
solutions with the addition of 150 mmol/l sodium bicar-
bonate may be an intravenous solution for rehydration
preferable to normal saline solutions17.
Potassium removal
Removal of potassium from the body can be achieved
by either loop or thiazide diuretics, dialysis, and cation-
exchange resins (Table 5).
Diuretics such as ethacrynic acid, furosemide, or thia-
zides inhibit tubular reabsorption of sodium chloride and
water, and stimulate potassium excretion. Although di-
uretics are not used specifically as primary agents for treat-
ing hyperkalemia, they are very useful for treatment of
chronic, mild hyperkalemia complicated with fluid reten-
tion25. Acute hyperkalemia is generally not treated opti-
mally with diuretics because the rate of potassium excre-
tion usually will not be adequate26.
Most of the patients with hyperkalemia have underly-
ing renal failure as a contributing factor, limiting the effec-
tiveness of diuretics. If pharmacologic agents are respon-
sible for hyperkalemia, such medications should be discon-
tinued (Table 1). In case of a rapidly reversible disease (e.g.,
obstructive uropathy), treatment of the underlying condi-
tion with close observation of the potassium level in asso-
ciation with continuous ECG observation may be adequate.
If CRF with decreased excretion of potassium is respon-
sible for hyperkalemia, dietary intake of potassium should
be restricted to less than 60 mmol/day.
Dialysis or continuous arterio(veno)venous hemofil-
tration may be used to remove potassium from the body
if medical interventions have failed to reverse hyperkale-
mia, or in case of massive release of cellular potassium as-
sociated with intercurrent hypercatabolism. Peritoneal
dialysis removes potassium at a slower rate reducing se-
rum potassium by 50% for every 12 hours of dialysis27.
Continuous arterio(veno)venous hemofiltration is effec-
tive in chronic hyperkalemia, but does not remove potas-
sium fast enough to be recommended for use in acute, se-
vere hyperkalemia. Hemodialysis is the most rapid
method of potassium removal (Fig. 4)28. If a potassium-
free dialysate is used, serum potassium may decrease as
much as 1.2 to 1.5 mmol/hour19. However, care should
be taken with the use of up to 2 mmol/l of potassium in
dialysate fluids to avoid precipitating hypokalemia29.
The resin, sodium polystyrene sulfonate (Kayexalate),
exchanges sodium for potassium in the gastrointestinal
tract, thereby allowing for potassium elimination. It can be
administered either orally or per rectum as a retention en-
ema. The rate of potassium removal is relatively slow (one
gram of sodium polystyrene sulfonate removes approxi-
mately 0.5 to 1.0 mmol of potassium in exchange for 2 to
3 mmol of sodium), requiring 4 hours for full effect17.
When given orally, sodium polystyrene sulfonate is gener-
ally administered with sorbitol (20 g of Kayexalate in 100
ml of 20% sorbitol) to avoid constipation. If given as an
enema, avoiding the use of sorbitol may be prudent because
several case reports suggest an association between rectal
administration of sodium polystyrene sulfonate with 20%
sorbitol and subsequent colonic perforation30.
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Sa¾etak
HIPERKALEMIJA: POTENCIJALNO POGUBNO KLINI¨KO STANJE
P. Kes
Hiperkalemija nastaje kao posljedica poremeæaja u unosu i izluŁivanju kalija, kao i zbog nerazmjera u razdiobi kalija izmeðu
izvanstaniŁnog i staniŁnog prostora. Radi se o Łestom, pritajenom, ali potencijalno smrtonosnom kliniŁkom stanju koje se
rijetko vidi u bolesnika s normalnom bubre¾nom funkcijom. NajznaŁajniji kliniŁki uŁinak hiperkalemija ima na srce, ali dovodi
i do poremeæaja u radu ¾ivaca i mi„iæa, probavnog sustava i ¾lijezda s unutarnjim luŁenjem. Prije lijeŁenja hiperkalemije
potrebno je iskljuŁiti la¾nu hiperkalemiju, prepoznati potrebu za hitnim lijeŁenjem i zapoŁeti s odgovarajuæom terapijom.
Hiperkalemiju koja ugro¾ava ¾ivot bolesnika treba gotovo uvijek poŁeti lijeŁiti inzulinom i glukozom, s obzirom na to da je
hipokalemijski uŁinak inzulina brz i predvidiv. Kombinirana uporaba inzulina i beta2-agonista je uŁinkovita, ali je hemodijaliza
metoda koja najbr¾e uklanja kalij iz organizma.
KljuŁne rijeŁi: Hiperkalemija, fiziopatologija; Hiperkalemija, terapija; Bubreg, fiziopatologija
